{"id":30,"date":"2017-09-15T16:05:01","date_gmt":"2017-09-15T16:05:01","guid":{"rendered":"https:\/\/wordpress-dev.med.unc.edu\/millerlab\/?page_id=30"},"modified":"2018-08-18T12:04:05","modified_gmt":"2018-08-18T16:04:05","slug":"novel-mouse-models-for-development-of-cellular-therapies-of-post-surgical-glioblastomas","status":"publish","type":"page","link":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/research\/novel-mouse-models-for-development-of-cellular-therapies-of-post-surgical-glioblastomas\/","title":{"rendered":"Novel mouse models for development of local therapies of post-surgical glioblastomas"},"content":{"rendered":"
\n

Surgery remains the mainstay of treatment options for patients with glioblastoma. However, these tumors diffusely infiltrate the normal brain and are resistant to adjuvant therapies such as radiation and chemotherapy. In collaboration with Shawn Hingtgen and Kristie Ainslie in the UNC Eshelman School of Pharmacy, we design novel mouse models of post-surgical glioblastoma to aid in the development of therapies targeted to post-surgical disease, including drug-eluting depots and cellular therapies that seek out and home to invasive cancer cells.<\/em><\/p>\n<\/header>\n

\n
\n

Project summary<\/h2>\n

The Miller Lab is focused on development of novel\u00a0genetically-engineered mouse<\/a>\u00a0(GEM) models of post-surgical glioblastoma that diffusely invade the normal brains of mice with an intact immune system.<\/p>\n

The Hingtgen Lab is focused on development of novel cellular delivery vehicles, particularly induced neural stem cells, that can seek out and home to invasive cancer cells.<\/p>\n

The Ainslie Lab is focused on development of novel polymeric drug delivery vehicles, particularly those using acetalated dextran scaffolds.<\/p>\n

\n

References<\/h2>\n
    \n
  1. Okolie O, Irvin DM, Bago JR, Sheets K, Satterlee A, Carey-Ewend AG, Lettry V, Dimitru R, Elton S, Ewend MG, Miller CR, Hingtgen SD.\u00a0 Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection.\u00a0 PLoS One.\u00a0 13(7):e0198596 Jul 2018.\u00a0 PMID: 29990322<\/a>\u00a0PMCID: PMC6038981<\/a><\/li>\n
  2. Graham-Gurysh EG, Moore KM, Satterlee AB, Sheets KT, Lin FC, Bachelder EM, Miller CR, Hingtgen S, Ainslie KM. Sustained delivery of doxorubicin via acetalated dextran scaffold prevents glioblastoma recurrence after surgical resection.\u00a0 Molecular Pharmaceutics.\u00a0 15(3):1309-1318 Mar\u00a0 PMID: 29342360<\/a>\u00a0 PMCID:\u00a0 PMC5999333<\/a><\/li>\n
  3. Bago JR, Okolie O, Dumitru R, Ewend MG, Parker JS, Vander Werff R, Underhill TM, Schmid RS,\u00a0Miller CR, Hingtgen SD.\u00a0 Tumor-homing cytotoxic human induced neural stem cells for cancer therapy.\u00a0 Science Translational Medicine.\u00a0 9(375):eaah6510 Feb 2017.\u00a0 PMID:\u00a028148846<\/a><\/li>\n
  4. Okolie O, Bago JR,\u00a0Schmid RS,\u00a0Irvin DM,\u00a0Bash RE,\u00a0Miller CR*, Hingtgen SD*.\u00a0 Reactive astrocytes potentiate tumor aggressiveness in murine glioma resection and recurrence model.\u00a0 Neuro-oncology.\u00a0 DOI: 10.1093\/neuonc\/now117 Jun 2016.\u00a0 PMID:\u00a027298311<\/a>\u00a0 *Co-senior authors<\/li>\n
  5. Bago JR, Alfonso-Pecchio A, Okolie O, Dumitru R, Rinkenbaugh A, Baldwin AS,\u00a0Miller CR, Magness ST, Hingtgen SD.\u00a0 Therapeutically engineered induced neural stem cells are tumor-homing and inhibit progression of glioblastoma.\u00a0 Nature Communications.\u00a0 7:10593 Feb 2016.\u00a0 PMID:\u00a026830441<\/a>\u00a0PMCID:\u00a0PMC4740908<\/a><\/li>\n<\/ol>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Surgery remains the mainstay of treatment options for patients with glioblastoma. However, these tumors diffusely infiltrate the normal brain and are resistant to adjuvant therapies such as radiation and chemotherapy. In collaboration with Shawn Hingtgen and Kristie Ainslie in the UNC Eshelman School of Pharmacy, we design novel mouse models of post-surgical glioblastoma to aid … Read more<\/a><\/p>\n","protected":false},"author":68816,"featured_media":0,"parent":10,"menu_order":6,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-30","page","type-page","status-publish","hentry","odd"],"acf":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages\/30","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/users\/68816"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/comments?post=30"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages\/30\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages\/10"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/media?parent=30"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}